Baxalta doses first patient in Phase I trial of BAX 826 to treat haemophilia A

US-based biopharmaceutical firm Baxalta has begun its Phase I clinical trial evaluating BAX 826, a recombinant Factor VIII (rFVIII) treatment for haemophilia A.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news